Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.96 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.96 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.96 |
| ▸ | NPC1 | O15118 | 1/20 | 0.96 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.96 |
| ▸ | HPGD | P15428 | 1/20 | 0.96 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.96 |
| ▸ | RAB9A | P51151 | 1/20 | 0.96 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | HRH1 | P35367 | 1/20 | 0.53 |
| ▸ | SCN1A | P35498 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.53 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.40 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL100361 | 1.00 | CYP2D6 (0.96) | CYP2D6MAPK1KDM4ENPC1CYP1A2 | |
| SCHEMBL239738 | 1.00 | CYP2D6 (0.96) | CYP2D6MAPK1KDM4ENPC1CYP1A2 | |
| SCHEMBL8136171 | 0.98 | CYP2D6 (0.93) | CYP2D6MAPK1KDM4ENPC1CYP1A2 | |
| SCHEMBL7446968 | 0.98 | CYP2D6 (0.93) | CYP2D6MAPK1KDM4ENPC1CYP1A2 | |
| Hydrochloric Acid SCHEMBL9277459 | 0.98 | CYP2D6 (1.00) | CYP2D6MAPK1KDM4ENPC1CYP1A2 | |
| Pipradrol SCHEMBL156360 | 0.95 | CYP2D6 (0.87) | CYP2D6MAPK1KDM4ENPC1CYP1A2 | |
| Pipradrol SCHEMBL4057811 | 0.93 | CYP2D6 (0.90) | CYP2D6MAPK1KDM4ENPC1CYP1A2 | |
| Sulfuric Acid SCHEMBL9452303 | 0.92 | CYP2D6 (0.82) | CYP2D6MAPK1KDM4ENPC1CYP1A2 | |
| SCHEMBL6295242 | 0.90 | CYP2D6 (0.79) | CYP2D6MAPK1KDM4ENPC1CYP1A2 | |
| SCHEMBL5054811 | 0.90 | CYP2D6 (0.79) | CYP2D6MAPK1KDM4ENPC1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 434 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3995492-B1 | A TWO-STEP PROCESS FOR PREPARING 3-SUBSTITUTED PHENYLALKYLAMINES | SpecGx LLC (US) | 2024-05-29 | — | — | EP | claimed |
| US-11993608-B2 | Selective estrogen receptor degraders | ELI LILLY AND COMPANY (US) | 2024-05-28 | — | — | US | claimed |
| US-20230234960-A1 | SELECTIVE ESTROGEN RECEPTOR DEGRADERS | ELI LILLY AND COMPANY | 2023-07-27 | — | — | US | claimed |
| CN-115260206-A | Estrogen receptor degradation agent, intermediate thereof, preparation method, pharmaceutical composition and application | 明慧医药（杭州）有限公司 | 2022-11-01 | — | — | CN | claimed |
| EP-3995492-A1 | A TWO-STEP PROCESS FOR PREPARING 3-SUBSTITUTED PHENYLALKYLAMINES | SpecGx LLC (US) | 2022-05-11 | — | — | EP | claimed |
| CN-107652274-B | Pentaerythritol immobilized (S) or (R) -diphenyl prolinol, and preparation method and application thereof | 石家庄学院 | 2020-07-21 | — | — | CN | claimed |
| CN-105884625-B | Synthetic method of R-salmeterol | 浙江工业大学 | 2018-11-13 | — | — | CN | claimed |
| CN-104829468-B | （R）The asymmetric preparation method of albuterol hydrochloride | 成都先基生化科技有限公司 | 2017-03-08 | — | — | CN | claimed |
| CN-105884625-A | synthetic method of R-salmeterol | 浙江工业大学 | 2016-08-24 | — | — | CN | claimed |
| CN-104326959-B | A kind of preparation method of Ezetimibe isomers | WUHAN WUYAO TECHNOLOGY CO., LTD. (CN) | 2016-05-25 | — | — | CN | claimed |
| US-20130030210-A1 | METHODS FOR PREPARING AMIDES AND AMINO ACIDS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2013-01-31 | — | — | US | claimed |
| US-8269039-B2 | Amino acids and catalytic preparatory methods | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2012-09-18 | — | — | US | claimed |
| CN-102584795-A | Preparing method of crizotinib | HONG TANG | 2012-07-18 | — | — | CN | claimed |
| US-20090264676-A1 | Amino acids and catalytic preparatory methods | WARF - WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2009-10-22 | — | — | US | claimed |
| US-20080176923-A1 | Proline Derivatives Used as Pharmaceutical Active Ingredients for the Treatment of Tumors | SALAMA ZOSER B | 2008-07-24 | — | — | US | claimed |
| EP-0873298-A4 | CHIRAL REDUCTIONS OF IMINES LEADING TO THE SYNTHESES OF OPTICALLY ACTIVE AMINES | NPS PHARMA INC (US) | 2000-05-17 | — | — | EP | claimed |
| US-5925666-A | DOPAMINE UPTAKE INHIBITORS; DRUG ABUSE AND DEPENDENCE, EATING DISORDERS, ATTENTION DEFICIT DISORDER, TOURETTE*S SYNDROME, GAMBLING | GUILFORD PHARMACEUTICALS INC. (US) | 1999-07-20 | — | — | US | claimed |
| WO-1999003467-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING COMPULSIVE DISORDERS USING PYRROLIDINE DERIVATIVES | GUILFORD PHARMACEUTICALS INC. (US) | 1999-01-28 | — | — | WO | claimed |
| EP-0873298-A1 | CHIRAL REDUCTIONS OF IMINES LEADING TO THE SYNTHESES OF OPTICALLY ACTIVE AMINES | NPS PHARMACEUTICALS, INC. (US) | 1998-10-28 | — | — | EP | claimed |
| WO-1997011934-A1 | CHIRAL REDUCTIONS OF IMINES LEADING TO THE SYNTHESES OF OPTICALLY ACTIVE AMINES | NPS PHARMACEUTICALS, INC. (US) | 1997-04-03 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130030210-A1 | METHODS FOR PREPARING AMIDES AND AMINO ACIDS | DNPEP, PTMS, QPCT | CYP2D6 1973/4885MAPK1 4782/4885KDM4E 2890/4885 |
| US-20230234960-A1 | SELECTIVE ESTROGEN RECEPTOR DEGRADERS | ESR1, GPER1, ESR2 | CYP2D6 154/4885MAPK1 3369/4885KDM4E 1011/4885 |
| US-11993608-B2 | Selective estrogen receptor degraders | ESR1, GPER1, ESR2 | CYP2D6 154/4885MAPK1 3369/4885KDM4E 1011/4885 |
| US-20090264676-A1 | Amino acids and catalytic preparatory methods | DNPEP, PREP, ENPEP | CYP2D6 2032/4885MAPK1 4540/4885KDM4E 2582/4885 |
| US-20080176923-A1 | Proline Derivatives Used as Pharmaceutical Active Ingredients for the Treatment of Tumors | PREP, PRAP1, VHL | CYP2D6 3249/4885MAPK1 4093/4885KDM4E 1762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.